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Abstract
Background: Ensuring good adherence is critical to the success of anti-retroviral treatment
(ART). However, in resource-poor contexts, where paediatric HIV burden is high there has been
limited progress in developing or adapting tools to support adherence for HIV-infected children on
ART and their caregivers. We conducted formative research to assess children's adherence and to
explore the knowledge, perceptions and attitudes of caregivers towards children's treatment.
Methods: All children starting ART between September 2002 and January 2004 (when ART was
at cost in Malawi) were observed for at least 6 months on ART. Their adherence was assessed
quantitatively by asking caregivers of children about missed ART doses during the previous 3 days
at monthly visits. Attendance to clinic appointments was also monitored. In June and July 2004, four
focus group discussions, each with 6 to 8 caregivers, and 5 critical incident narratives were
conducted to provide complementary contextual data on caregivers' experiences on the challenges
to and opportunities of paediatric ART adherence.
Results: We followed prospectively 47 children who started ART between 8 months and 12 years
of age over a median time on ART of 33 weeks (2–91 weeks). 72% (34/47) never missed a single
dose according to caregivers' report and 82% (327/401) of clinic visits were either as scheduled, or
before or within 1 week after the scheduled appointment. Caregivers were generally
knowledgeable about ART and motivated to support children to adhere to treatment despite facing
multiple challenges. Caregivers were particularly motivated by seeing children begin to get better;
but faced challenges in meeting the costs of medicine and transport, waiting times in clinic, stock
outs and remembering to support children to adhere in the face of multiple responsibilities.
Conclusion: In the era of rapid scale-up of treatment for children there is need for holistic support
strategies that focus on the child, the caregiver and the health worker and which are situated within
the reality of fragile health systems. The findings highlight the need for cost-free and less complex
paediatric ART regimes and culturally appropriate tools to support children's adherence.
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Background
The availability of anti-retroviral therapy (ART) has led to
a reduction of morbidity and mortality in people living
with HIV/AIDS. The push to provide ART for HIV infected
children has recently gained considerable momentum in
Africa, where HIV prevalence rates are high [1,2]. For
example Malawi, with a population of approximately 13
million people, had an estimated 900,000 people infected
with HIV in 2007, among them 90,000 children less than
15 years. Approximately 85,000 people were newly
infected with HIV and 61,000 children and adults died
due to AIDS [3]. Malawi has made impressive strides in
scaling up access to ART. By 30th  September 2008,
208,440 patients (8% children) had been registered for
ART in public and private clinics and 66% of those are
alive and on ART [4].
In line with the equity in ART policy, ART has been pro-
vided free on a first come – first served basis since June
2004. However, using HIV prevalence rates amongst
blood donors to estimate national prevalence, it was
found that in March 2005, only an estimated 5.1% of peo-
ple in need of ART were accessing ART [5]. The equivalent
rate amongst children was 3.1%, suggesting that children
may face even bigger barriers to ART access than adults
(ibid.). Despite this proportion has now increased, litera-
ture and key informant interviews suggest that barriers
still exist and are related in part to ART sites not reaching
their full capacity to provide treatment for children, the
need for longer and more complex consultation proce-
dures and related opportunity costs, transport costs and
stigma. Strategies to enhance children's ART access
became an area of critical advocacy in Malawi as part of
the global WHO/UNICEF children and AIDS campaign
[6,7].
Understanding ways to promote children's adherence to
ART is also vital. In adults, 95% adherence is necessary to
reduce the development of drug resistance and for drugs
to work effectively in prolonging life [8]. Likewise, non-
adherence is a predictor of rapid disease progression [9].
Studies, which examine ART adherence among children
are largely from developed world settings, utilize a variety
of measurements and associate adherence with immuno-
logical and virological markers [10-13]. Studies from low
and middle-income countries were recently reviewed and
the lack of cultural adaptation of tools to measure adher-
ence as well as the lack of formative qualitative research
has been identified as a gap [14].
Measuring adherence to ART is fraught with difficulties
and there is no gold standard. Direct measurement
approaches identified in the literature include observation
[15], and assessment of drug levels [16,17]. Indirect meas-
urement approaches include pill counts [18-20], patient
reported intake [12,21], physician's assessment [13],
number of prescriptions filled [10] and electronic moni-
toring, using for example the Medication Event Monitor-
ing System (MEMS), whereby the opening of bottles of
drugs is electronically recorded [13,22]. Measuring adher-
ence is further complicated amongst children because
some of these methods are not appropriate, for example
the pill count is complicated by different formulations
(the use of syrups) and varying dosage dependent on
weight and body surface [23]. There are also additional
challenges in resource-poor contexts and it has been
argued that in Africa adherence will not be as good as in
settings, which can afford resource-intensive programmes
[24]. However, evidence is increasing that adherence of
children in low and middle income countries might be
equal if not better than in high income countries, where
most studies have shown adherence rates of less than 75%
[14]. For example, good adherence using a simple tool
like measuring pills returned to the clinic was correlating
with viral load suppression in Cape Town, South Africa
[25]. In another study with good clinical and immunolog-
ical outcomes, adherence was measured by caregiver's and
child's self report [26]. However, further research on
adherence in African countries is urgently needed [27]
and results might be different in rural settings [28]. The
contribution of factors like disclosure status of the child is
still controversial [29,30].
This article merges findings from two complementary
studies (one quantitative, one qualitative) conducted at
the Lighthouse in urban Lilongwe, Malawi, with the aim
to contribute to the debate on developing strategies to
support ART adherence amongst children in resource-
poor contexts. The objectives are (1) to describe the char-
acteristics and outcomes of children on ART (quantitative)
(2) to describe children's adherence according to sched-
uled appointments and caregivers' report of ART intake
(quantitative) (3) to explore caregivers' perceptions of bar-
riers and enabling and motivating factors to adhering to
ART for children (qualitative).
Methods
Study setting
The Lighthouse Clinic is located in urban Lilongwe,
Malawi, at the campus of the central hospital. Lighthouse,
a charitable trust since 2001, functions as a part of the
public health sector and provides care for people affected
by and infected with HIV/AIDS. Services include HIV test-
ing and counselling, home based care and clinical care,
including – since July 2002- ART. Public health services in
Malawi are offered free at the point of delivery, and ART
has been provided free since June 2004. It is important to
note that the studies took place when patients had to pay
for treatment and a month's supply of paediatric formula-
tion (depending on weight band and drugs used) ranged
from USD14 to 43.BMC Pediatrics 2009, 9:45 http://www.biomedcentral.com/1471-2431/9/45
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Lighthouse has standardized procedures for visits, includ-
ing initial visits, follow-up visits and initiation of ART for
children. For each child initiating ART, a master-card with
name, age, ID number and scheduled visit dates is pre-
pared and kept in a separate folder and reinforces infor-
mation recorded in a child's health passport or treatment
card. Before starting ART, the caregiver and the child (if
the diagnosis was disclosed) attend a one-hour manda-
tory education session.
Description of weight-band based ART regimens used 
during the study period
The initial regimen used for children at Lighthouse was
AZT, 3TC and NVP (see additional file 1: ART- regimen a).
Several formulations were used, at different prices: generic
AZT syrup, AZT 100 mg capsules, generic 3TC syrup,
generic 3TC 150 mg tablets, generic NVP syrup and 200
mg NVP tablets. A limited number of 3TC 150 mg tablets
and AZT 100 mg capsules were free of charge during the
study period through donations. According to patients'
body weight and body surface tablets had to be split into
halves and commercial pill cutters were supplied. The first
edition of the national ART guidelines [31] recommended
d4T, 3TC and NVP for both adults and children as first
line ART regimen. From January 2004 onwards, new chil-
dren started on a combination of generic dual combina-
tion tablets of d4T/3TC and single generic NVP tablets
(see additional file 2: ART- regimen b). When they
reached 25 kg body weight they started or switched to
adult fixed dose combination (FDC) of d4T 30 mg/3TC/
NVP (Triomune 30) 1 tablet twice daily. By July 2004,
only 3 of 29 children were still on their initial regimen of
AZT/3TC and NVP.
Quantitative methods
All children less than 13 years of age who started ART at
the Lighthouse between 1st September 2002 and 31st Jan-
uary 2004 were enrolled in the study and observed until
31st July 2004. The basic characteristics of children on ART
and outcome measures were assessed through analysis of
the master card at baseline and at the end of the study
period. After a child's initial visit to the clinic, a main car-
egiver was identified and an appointment for the weekly
paediatric clinic was given. Eligibility for ART treatment
was defined immunologically and clinically using WHO
stages I to III according to WHO guidelines [32]. In addi-
tion, caregivers were informed about the cost of the treat-
ment and children started only if caregivers confirmed
that they could afford ART. However, no detailed assess-
ment of caregivers' ability to afford ART was done. Prior to
ART initiation the caregiver received an information leaf-
let. After initiation of ART children were given appoint-
ments after 2 weeks and thereafter visited the clinic at
monthly intervals. During each ART visit caregivers were
asked to report missed ART doses within the last 3 days
prior to the visit according to the format below:
Is your child on long-term treatment (like ARV, CPT,
IPT, TB tx)? Y/N, if yes, specify ____________________
How many doses did he/she miss yesterday? _______
The day before that? __________
The day before that? __________
When was the last time your child missed a dose of
medication? _________
What keeps him/her from taking the medication? (If
your child is on ARV, the question above relates to
ARVs. Otherwise indicate to which other long-term
treatment it relates)
Appointments were monitored from the child's first visit
at the Lighthouse. Once on ART, each caregiver's report of
their children's ART intake was recorded for at least 6
months. All quantitative measures were entered into an
MS Excel spreadsheet and regularly updated.
Qualitative methods
To complement the quantitative data, a qualitative study
was conducted in June and July 2004, when free ART and
an increased uptake of ART was imminent. Two comple-
mentary qualitative methods were used: focus group dis-
cussions (FGD) and critical incident narrative (CIN), a
form of in-depth interview, which trace a particular ill-
ness-experience through time (in this case the pathway to
initiation of ART and experiences since then). During 4
FGDs, each with 6 to 8 female caregivers, barriers for chil-
dren to adhere to ART were explored. In 5 CINs, experi-
ences of different female and male caregivers of HIV-
infected children on ART, and of children who were lost
to follow-up or interrupted treatment, were examined.
Qualitative data collected from the FGDs and CINs were
transcribed verbatim. Following the framework approach
to qualitative analysis [33] the FGD and CIN transcripts
were analysed with codes to identify key themes emerging
and comparing and contrasting the views and experiences
of different respondents.
Ethics and quality assurance
The Malawian National Health Sciences Research Com-
mittee approved both studies. In addition, the quantita-
tive study was approved by the London School of Hygiene
and Tropical Medicine ethics committee, UK, and the
qualitative study by the Liverpool School of Tropical Med-
icine ethics committee, UK. Quality was assured in the
quantitative study through regular audit of the patient's
file and comparison against entries in the excel spread-
sheet, and in the qualitative study through the skills of aBMC Pediatrics 2009, 9:45 http://www.biomedcentral.com/1471-2431/9/45
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senior social scientist with experience of conducting qual-
itative research on HIV in Malawi (IM).
Results
Quantitative results I: Characteristics and outcomes of 
children on ART
Table 1 shows the baseline characteristics of the 47 chil-
dren as they started ART. Their median time on ART was
33 weeks (range 2–91).
The cumulative outcomes as of 31st July 2004 were as fol-
lows: 36 children were alive and on ART, 5 were lost to fol-
low-up (not seen in the clinic for 3 months after picking
up their last one-month supply of ART), 3 children died
and 3 children discontinued ART. Of those who discon-
tinued, one child started d4T/3TC and NVP and devel-
oped abdominal distension with hepatomegaly and
ascites after 8 weeks on ART. Lab investigations were not
available through the central hospital. The presumptive
diagnosis of NVP- associated hepatitis was made and ART
had to be permanently stopped since no alternative triple
combination was available. The two other children had
started on AZT, 3TC and NVP but stopped because car-
egivers could not afford to continue ART after 12 and 4
months, respectively. One child continued to be in fol-
low-up and re-started when ART became free, but outside
the study period.
Quantitative results II: Strategies to assess adherence
Scheduled appointments
In total, 451 appointments for the 47 children before and
on ART were recorded. Due to incomplete records (no
date of visit entered in the visit form, no appointment
given), 401 were available for analysis (Table 2).
More than 80% of all visits (327/401) were either as
scheduled, before the agreed day or within a week (the
paediatric clinic is once a week). Fifteen out of the 47 chil-
dren never came more than one week late, 9 came more
than a week late once and 12 came more than a week late
twice. Thirty-one out of 47 patients made visits before
their agreed appointment, and the most common reasons
for coming earlier were acute illnesses, anticipated side
effects, and forgetting the appointment date.
Self report
Once on ART, caregivers were asked at each visit whether
doses had been missed in the previous 3 days. In total,
441 ART-visits were recorded. Complete information was
available for 363 visits. Thirty-four out of 47 children
never missed a single ART dose within the last 3 days
according to the caregivers' report. Visits of these children
account for 73% of all visits available for analysis. Car-
egivers of 13 children, accounting for the remaining 27%
of all visits, reported missing doses once or twice during
17 visits. The following reasons for missed doses were
given during these 17 visits: no drugs at home for different
reasons-5 (no stock in pharmacy- 1, no money to buy- 2,
no specific reason given- 2), mother went to work early –
2, travelling-2, child was hospitalised and semiconscious
due to an road traffic accident- 1, child was vomiting- 1,
had visitors- 1, no reason given- 5. Seven out of these 13
patients with missing doses did not visit the clinic at the
agreed date the day they reported the missing and 6 visited
on time. These 7 patients made 9 visits with reported
missed doses: 6 visits were within a week after the
appointment, 2 visits more than a week after the appoint-
ment, and 1 visit was before the appointment.
Thirty-two patients visited the clinic at least once within a
week after the actual appointment date. Out of those, 27
patients had delayed visits while on ART. Twenty-one
reported not having missed any ART dose within the 3
days prior to their (delayed) visit, 4 patients reported dur-
ing at least one delayed visit to have missed a dose, and for
delayed visits of 2 patients on ART there was no adherence
information available. Therefore, not more than 6 out of
27 patients with delayed ART visits up to one week
Table 1: Baseline characteristics of children included in the 
quantitative study
Total number of patients 47
Male 24
Female 23
Age at start of ART (months) Median (range) 98 (8–151)
WHO stage II 22
III 25
Immunological stage I 1
II 8
III 36
Not classified 2
Table 2: Adherence with scheduled appointments (including 
visits while not on ART)
Total no. of visits with appointments given (%) 401 (100)
As scheduled 206 (51)
Before appointment 58 (15)
Within 1 week after appointment 63 (16)
More than 1 week after appointment 74 (18)BMC Pediatrics 2009, 9:45 http://www.biomedcentral.com/1471-2431/9/45
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reported to have missed doses during their delayed visits.
Twenty-two out of 36 children alive and on ART by the
end of July 2004, were fully adherent according to caregiv-
ers' reports throughout the study period. They never
reported to have missed any dose over the past three days
and they never mentioned, that they had missed a dose in
response to the question "When was the last time your
child missed a dose of medication?"
Qualitative results: caregivers' understanding of ART and 
perceived barriers and enablers for adherence
'Assisting soldiers in the body': Understanding and administering ART
In general caregivers showed a good understanding of
how ART works. Many respondents referred to ART as
'bringing back immunity', 'adding to immunity' or 'assist-
ing soldiers in the body who fight with illnesses'. Most
caregivers understood that ART had to be taken on a regu-
lar basis for life, for example:
'It is through the child's life because you want the immunity
of the child to be at a good level so that the virus should not
multiply itself a lot and if he stopped taking them the virus
might get used to the medicine and start to multiply again'
(CIN, female caregiver)
However, one female caregiver understood that children
stop taking treatment when they reach 15 years of age.
Caregivers were able to explain that dosage was depend-
ent on the child's age and some female caregivers also
made the association with weight. Most respondents
reported that it was the mother or female caregiver who
gave the drugs to the child and also accompanied the
child to the Lighthouse. One caregiver of a child who had
defaulted from treatment reported that the child took the
drugs on his own as he was staying in the village with his
grandmother. Most caregivers reported that they did not
face major challenges in children taking drugs. This was
mainly attributed to the fact that the child had been sick
for a long time and was used to taking drugs. However,
one woman explained that a child she was caring for
would keep the drugs in his mouth for a long time and
spit them out later. All respondents mentioned that chil-
dren suffered from side effects of ART. Common condi-
tions attributed to the ART and classified by the caregivers
as side effects were: rash, stomach pains, leg swelling and
pain, diarrhoea, coughing, vomiting, and yellow eyes.
'He is able to play': Enablers for adhering to ART
Positive visual and physical changes emerged as the key-
motivating factor in supporting children to adhere to ART.
'I feel that there has been a great change because at the time
he was starting, he had low weight and his stomach was big
but after he started he changed and he was not very sick.
Now he has changed, after the medicine he is able to play'
(CIN, female caregiver to a child on ART for 12
months)
It was also generally felt that ART reduced the time that
caregivers had been spending with a child admitted to
hospital, as well as the time lost from economic activities
as explained in the quotes below.
'She is not getting as sick as before and since she started
treatment she has not been admitted to hospital' (CIN,
female caregiver to a child on ART for 13 months)
'The child's frequent illness usually affected us, as our
assistance is required and if we do not have money, we have
to find some and we also have to bring the child to the hos-
pital which means we cannot go to work and therefore also
affects our home' (CIN, male caregiver to a child starting
ART)
Love and commitment to the child also emerged as key
themes and were important in supporting the child to
adhere to ART. Female caregivers in both the FGD and
CINs highlighted the importance of good planning in
supporting adherence, such as giving the drugs before a
mother goes to work, and ensuring that the child does not
run out of drugs. Women also reported that the children
themselves sometimes reminded them if they forgot to
give them the drugs.
Multiple challenges: Barriers to adhering to ART
Cost stood out as the key barrier and caused children to
attend late to appointments and to miss doses. The car-
egivers of children from orphanages feared that the chil-
dren would run into problems if at any time sponsors
would stop giving money for ART. Some respondents also
explained that caregivers considered deliberately reducing
the doses to make the drugs last longer. Some participants
were living outside of Lilongwe and had to travel long dis-
tances to come to the Lighthouse. As a result, cost of trans-
port and time spent for travelling increased. One
respondent, whose child had been lost to follow-up and
was traced during the study, explained that the child had
constantly missed drugs because he was living with his
grandparents. They had not been supervising him in tak-
ing treatment and had left the child with the responsibility
of taking his drugs as required. The respondent also
reported that the child stayed with the grandparents in
Rumphi (400 kilometres from Lilongwe) and at the time
the child needed to go to the Lighthouse, they did not
have money for transport.
'When I went to attend the funeral I asked his granny
because I saw that the drugs were finishing to help me with
money [so she could pick the child to get his drugs] but she
refused saying that she did not have money. The problem forBMC Pediatrics 2009, 9:45 http://www.biomedcentral.com/1471-2431/9/45
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me is that my husband died and I stay by myself and it is
difficult to find money.' (Female caregiver, child lost to
follow-up)
Multiple responsibilities of caregivers were identified as
another barrier. Children of caregivers who worked or per-
formed other activities outside their homes, or who dele-
gated the responsibility of administration of drugs to
housemaids or other household members, were at higher
risk to miss doses.
'When I had to leave early for work I could leave his father
to give him the drugs but his father could forget to do so'
(CIN, female caregiver to a child on ART for 12
months)
Multiple responsibilities were a particular constraint for
caregivers at orphanages as illustrated by the following
quote:
'What sometimes happens is that I look after many children
and sometime I get very busy as I am looking after 11/12
children, so maybe sometime something sudden can hap-
pen. May be one of the other children is ill or has been
injured and you can get distracted by these other things but
still if it is evening and you forgot you have to wake the
child up and give them the drugs' (CIN, female caregiver
to a child on ART for 11 months)
Other barriers that emerged were changes of the routine,
for example giving responsibility to someone else to give
the drugs if the main caregiver is away, for example
attending a funeral. This was further complicated by
stigma and fear of disclosure and some participants faced
difficult decisions about whom to ask to support drug
adherence amongst children in their absence. Death of
caregiver was highlighted as a particular challenge to
adherence. A male caregiver reported that his child was
missing cotrimoxazole preventive therapy (CPT) because
he had left his sister to give the drugs to the child. Travel-
ling and visiting relatives could also cause problems in
adherence to drugs. In some cases, the responsibility for
drug taking was left largely to the child:
'The problem could be that he looks after himself but he is
still a child and of course sometimes his granny reminds
him but you know sometimes they can go to attend a funeral
and the child ends up being alone at home' (CIN, female
caregiver to a child lost to follow-up)
One respondent stated that once a child started to feel bet-
ter, the caregiver might feel less inclined to insist that the
child takes ART on a regular basis. System-related barriers
were also cited, such as the Lighthouse running out of
drugs and long waiting times.
Discussion
According to the caregivers' reports 72% (34/47) of chil-
dren never missed a single ART dose, suggesting that 34
children had complete (100%) adherence over the full
study period for the 3 days prior to each visit. More than
80% of all children's visits occurred within a week of the
agreed day. It appears that relatively high levels of adher-
ence confirmed by these two different quantitative find-
ings are further corroborated by favourable major clinical
outcomes in this group of children with advanced HIV
disease (77% alive and responding to treatment after a
median treatment duration of 33 weeks). However, inter-
pretation of these findings needs to be treated with cau-
tion. First, caregivers' report has a low sensitivity to detect
poor adherence [25]. We did not have the means to per-
form more objective measurements, like drug plasma lev-
els, or viral load tests because of cost. We could not use
pill counts as a measure because we used pills, capsules
and syrups concurrently. Monitoring pharmacy refills was
difficult because caregivers bought ART for their children
at different pharmacies at the central hospital or in private
pharmacies in town. Second, our sample size is small
making interpretation of clinical outcomes challenging.
The sample size reflects the reality of the limited number
of children who were on ART at the time of study: the 47
children represent the complete cohort of children who
started ART at Lighthouse within this period. However,
outcomes in other studies from Malawi are similar
[34,35]. Third, a comparison with adherence reported by
others is difficult; tools used to measure adherence are
heterogeneous and poorly validated [14]. Exact provision
of a one-month supply of anti-retrovirals (ARVs) is diffi-
cult if different formulations (split tablets and syrups) are
used. ARVs remaining from previous supplies or missed
doses during time periods prior to the 3-day recall can
allow patients to report complete adherence at a delayed
visit or can result in over-reporting of adherence with
ARVs. The importance of regularly asking questions about
missed doses might lie more in reminding and motivating
caregivers to support adherence than actually measuring
adherence. Providers should emphasize on taking full
doses and not pill sharing (as mentioned in an FGD) in
ongoing patient communication.
The complementarity of multi-method research is well
recognised in the literature, with findings from qualitative
research helping to interpret and contextualise quantita-
tive results [36-38]. In our research, the qualitative study
clearly highlights that caregivers are well motivated to
support children in adhering to ART, despite the multiple
challenges this presents. Seeing a child become much
healthier after taking ART is a strong adherence motivator,
despite the perceived side effects. A positive treatment
response strongly reinforces adherence [39]. If ART is
started too early it is possible that negative side effects willBMC Pediatrics 2009, 9:45 http://www.biomedcentral.com/1471-2431/9/45
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outweigh the perceived positive effects of ART with impli-
cations for adherence.
The studies took place within a clinic with well-trained
and well-motivated staff at the time when patients had to
pay for ART [40]. The ART regimens used were complex
depending on the particular situation of the patient and
drug availability. The situation at the Lighthouse is now
remarkably different and should arguably further rein-
force adherence. The regimen currently used, in line with
the national ART scale-up policy, is simpler, easier to pro-
cure and always available. With funding from the Global
Fund, ART is now provided free, meaning that patients no
longer face the key adherence barrier of cost of drugs. This
is an extremely positive step, which has the potential to
enhance access to ART for poor adults and children alike
[5]. However, free drugs had meant increased demand for
ART and waiting times were prone to being much longer
than they used to be. Anecdotal evidence highlights that
this had led to patient dissatisfaction and possibly default-
ing from care [41].
By March 2005, 34 public health facilities provided ART;
886 children in 13 of these sites (<13 years) had registered
for ART, representing 5% of the total cohort [42]. ART is
now available in 170 public sites throughout Malawi and
16,600 children (<15 years) have started ART in the public
sector, representing 8% of the total cohort [4]. However,
many sites face severe human resource shortages [43]
resulting in long waiting times, also confidence and exper-
tise in paediatric HIV care is still limited. Results of this
study have fuelled the discussion about user fees for ART
in Malawi [44] and contributed to debates on how to
address the urgent need to support complementary, user-
friendly approaches to supporting adherence in children,
who have potentially a whole lifetime of drug-taking
ahead of them. A paediatric ART flip chart was developed
through a similar process as the adult ART flip chart and
rolled out in the country [45]. We hope this tool will con-
tribute to sustaining the paediatric 1st line regimen longer
since second line drugs are only available in few sites, can
be more complex, more difficult to adhere to and more
expensive.
International guidelines still rely largely on western con-
cepts with little contribution of qualitative research to
address cultural context and overburdened health facili-
ties to support children's adherence to ART in resource-
poor contexts [14,46]. This narrow focus is not appropri-
ate. The findings from the 2 studies presented here clearly
show the need for contextual understandings and holistic
responses that are grounded in health workers', caregivers'
and children's experiences, and the challenges and priori-
ties in resource-poor contexts. Malawi is now addressing
adherence with paediatric ART [47,48].
The need for a holistic approach is supported by research
on adherence amongst children and adolescents in
resource-rich countries which highlights the importance
of focusing on patient characteristics and the 'triadic
nature of the doctor-caregiver-child relationship' [49].
Treatment outcomes are dependent on adherence, which
in turn is dependent on a complex array of systems, indi-
vidual and socio-cultural related barriers. In resource-
poor contexts, system-related factors appear to be strong
determinants of adherence. It is imperative for children to
be able to stay as long as possible on first line ART in
resource-poor contexts, such as Malawi. Hence these mul-
tiple factors need to be addressed in a holistic approach in
order to maximise chances of supporting children's adher-
ence to ART in resource-poor countries.
Conclusion
It is possible for children in resource-poor contexts to
access and adhere to ART. The launch of the WHO/
UNICEF global initiative on children and AIDS has
pushed this agenda forward [6]. Quantitative and qualita-
tive insights from the Lighthouse in Lilongwe have shown
that caregivers and children are well motivated to adhere
despite the presence of both individual, familial and
health-system related barriers. User-friendly pragmatic
structures can be put in place (such as caregivers' report,
appointment monitoring and pill count measurements)
to monitor, assess and support adherence in challenging
resource-poor contexts. In supporting adherence there is a
need for a holistic and contextually bound approach that
encompasses the priorities of health providers, caregivers
and children.
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